Invesco S&P World Health Care ESG UCITS ETF AccumUSD (GB:WHCE) Price & Chart
GB:WHCE ETF Chart & Stats
- Day’s Range
- $7.42 - $7.42
- 52-Week Range
- $5.96 - $7.42
- Previous Close
- $7.28
- Volume
- 7,571
- Average Volume (3M)
- 2,257
- AUM
- 13.13M
- NAV
- 7.39
- Expense Ratio
- 0.20%
- Holdings Count
- 67
- Beta
- 0.85
- Inception Date
- Apr 12, 2023
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 1,800,000
- Standard Deviation
- N/A
ETF Overview
Invesco S&P World Health Care ESG UCITS ETF AccumUSD
The Invesco S&P World Health Care ESG UCITS ETF AccumUSD, trading under the ticker GB:WHCE, offers investors a unique opportunity to engage with the global health care sector through an environmentally and socially responsible lens. This exchange-traded fund is meticulously designed to track the performance of the S&P Developed Ex-Korea LargeMidCap ESG Enhanced Health Care Index. By focusing on this specific sector, the fund provides exposure to a diverse array of companies dedicated to advancing medical innovations, pharmaceuticals, biotechnology, and health care equipment worldwide. What sets the Invesco S&P World Health Care ESG UCITS ETF apart is its commitment to sustainability and ethical investment practices. It seeks to align investors' financial goals with their values by incorporating environmental, social, and governance (ESG) criteria into its selection process. This ensures that the companies included in the ETF not only have a robust financial outlook but also adhere to high standards of corporate responsibility and sustainable practices. Ideal for investors who are keen on capitalizing on the steady growth and innovation within the health care sector, this ETF also caters to those who are conscientious about the broader impact of their investments. By focusing on a broad-based yet niche market, this fund provides a balanced approach to sector-specific investing, making it an attractive option for those looking to diversify their portfolios with a focus on ethical health care advancements.